Synonyms: Bisolvon® | NA-274 | NA274
bromhexine is an approved drug
Compound class:
Synthetic organic
Comment: Bromhexine is a widely used mucolytic (expectorant) drug. In response to the SARS-CoV-2 pandemic of 2019/20 it was investigated as an add-on treatment for patients with COVID-19 [1]. In addition to its mucolytic activity, bromhexine may also inhibit the human protease TMPRSS2 that is exploited by certain coronaviruses for spike (S) protein priming, thus reducing the viruses' infection mechanism [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Bromhexine is a component of expectorant cough medicines. It is not approved by the FDA or EMA, but is authorised for clinical use in many other countries. In the UK it is used only in veterinary medicine. Clinical trials in patients with COVID-19 are underway in a number of countries including Iran (trial 46969), Russia, Slovenia, China and Mexico. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04355026 | Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia | Phase 4 Interventional | General and Teaching Hospital Celje | ||
NCT04424134 | BromhexIne And Spironolactone For CoronаVirUs Infection Requiring HospiTalization | Phase 3 Interventional | Lomonosov Moscow State University Medical Research and Educational Center | ||
NCT04405999 | Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease | Phase 4 Interventional | Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health |